ArticleOncoimmunology
PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma.
Abstract read
In one paragraph
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Role of PD-L1 Expression as a Predictive Biomarker in Esophageal Cancer: a Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Visualizing the distribution of durvalumab targeting PD-L1 using quantitative fluorescence imaging in patients with esophageal cancer.Theranostics · 2026Article
- The expression and prognostic predictive value of PD-L2 in patients undergoing radical gastric cancer surgery.Future science OA · 2025Article
- Multimodal deep learning for predicting PD-L1 biomarker and clinical immunotherapy outcomes of esophageal cancer.Frontiers in immunology · 2025Article
- Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer.Cancer immunology, immunotherapy : CII · 2023Review
- PDL1-Based Nomogram May Be of Potential Clinical Utility for Predicting Survival Outcome in Stage III Breast Cancer.Breast cancer (Dove Medical Press) · 2023Article
- Scientific Research Directions on the Histopathology and Immunohistochemistry of the Cutaneous Squamous Cell Carcinoma: A Scientometric Study.Medicina (Kaunas, Lithuania) · 2022Article
- Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells.Scientific reports · 2022Article
- Impact of the Tumor Microenvironment for Esophageal Tumor Development-An Opportunity for Prevention?Cancers · 2022Review
- Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer.Cancers · 2022Review
- Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.The Journal of pathology · 2022Article
- Association of the programmed death ligand-1 combined positive score in tumors and clinicopathological features in esophageal cancer.Thoracic cancer · 2022Article
- Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis.Frontiers in oncology · 2022Article
- c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.Clinical and translational medicine · 2021Article
- Histone Modifying Enzymes as Targets for Therapeutic Intervention in Oesophageal Adenocarcinoma.Cancers · 2021Review
- Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival.Oncoimmunology · 2021Article
- CHID1 Is a Novel Prognostic Marker of Non-Small Cell Lung Cancer.International journal of molecular sciences · 2021Article
- Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy.European surgery : ACA : Acta chirurgica Austriaca · 2021Article
- Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study.Annals of gastroenterological surgery · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Dagmar KollmannDepartment of Surgery and Comprehensive Cancer Center, GET-Unit, Medical University of Vienna, Vienna, Austria.
Desislava IgnatovaDepartment of Dermatology, University Hospital Zürich, University of Zurich, Zurich, Switzerland.
Julia JedamzikDepartment of Surgery and Comprehensive Cancer Center, GET-Unit, Medical University of Vienna, Vienna, Austria.
Yun-Tsan ChangDepartment of Dermatology, University Hospital Zürich, University of Zurich, Zurich, Switzerland.
Gerd JomrichDepartment of Surgery and Comprehensive Cancer Center, GET-Unit, Medical University of Vienna, Vienna, Austria.
Andreas BaierlDepartment of Statistics and Operations Research, University of Vienna, Vienna, Austria.
Dmitry KazakovDepartment of Pathology, Charles University, Biomedical Center, Faculty of Medicine in Plzen and Charles University Hospital Plzen, Plzen, Czech Republic.
Michal MichalDepartment of Pathology, Charles University, Biomedical Center, Faculty of Medicine in Plzen and Charles University Hospital Plzen, Plzen, Czech Republic.
Lars E FrenchDepartment of Dermatology, University Hospital Zürich, University of Zurich, Zurich, Switzerland.
Wolfram HoetzeneckerDepartment of Dermatology, University Hospital Zürich, University of Zurich, Zurich, Switzerland.
Tobias SchattonHarvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Reza AsariDepartment of Surgery and Comprehensive Cancer Center, GET-Unit, Medical University of Vienna, Vienna, Austria.
Matthias PreusserClinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, GET-Unit, Medical University of Vienna, Vienna, Austria.
Michael GnantDepartment of Surgery and Comprehensive Cancer Center, GET-Unit, Medical University of Vienna, Vienna, Austria.
Emmanuella GuenovaDepartment of Dermatology, University Hospital Zürich, University of Zurich, Zurich, Switzerland.
Sebastian F SchoppmannDepartment of Surgery and Comprehensive Cancer Center, GET-Unit, Medical University of Vienna, Vienna, Austria.
Funding
EPA EP-C-17-023EPA EP-D-17-023
Abstract
PubMed holds no abstract for this paper.
Indexed as
esophageal adenocarcinomaesophageal carcinomaPD-1PD-L1PD-L2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.